Literature DB >> 1618245

Differences in antidiabetic drug utilisation between three different health systems in the same national region.

J Benítez1, A M Puerto, J A Díaz.   

Abstract

The consumption of antidiabetic drugs in a Spanish region (Extremadura) in the period 1986-1987 has been investigated by the "defined daily dose" (DDD) method. The study was done in three health care systems in the region: civil servants ("Mutualidad de Funcionarios Civiles del Estado: MUFACE") armed forces group ("Instituto Social de las Fuerzas Armadas: ISFAS") and the national system ("Instituto Nacional de la Salud: INSALUD"). The total consumption of antidiabetic drugs varied three-fold, ranging from 5,73 DDD per 1000 inhabitants per day (3,71 DDD per 1000 inhabitants per day for oral antidiabetic drugs and 2,02 DDD per 1000 inhabitants per day for insulin) in the civil servant group to 15,82 DDD per 1000 inhabitants per day (12 DDD per 1000 inhabitants per day for oral antidiabetic drugs and 3,82 DDD per 1000 inhabitants per day for insulins) in the armed forces. The differences were more pronounced for oral antidiabetics than for insulins. The utilization of insulin among the civil servants was about half of that by the two other groups. Of oral antidiabetics, sulphonylureas were the most frequently used by the three groups, and within them glibenclamide accounted for more than half of the DDDs, while biguanides were scarcely used in any group. The differences are difficult to assess, since they could be due to several factors, such as age-differences in the population studied, different prescribing habits, and differences in sociocultural level. The results justify further comparative studies of drug utilization in different health systems within the same region.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618245     DOI: 10.1007/bf00278475

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Comparative consumption of antidiabetic drugs in Britain, France and Germany.

Authors:  F Taboulet
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Patterns in drug utilization--national and international aspects: antihypertensive drugs.

Authors:  I Baksaas
Journal:  Acta Med Scand Suppl       Date:  1984

3.  A community pharmacy-based survey of antihypertensive and antidiabetic drug dosages in Northern Ireland.

Authors:  K Griffiths; D G McDevitt
Journal:  J Clin Hosp Pharm       Date:  1983-06

4.  Utilization of antidiabetic drugs in the Island of Gotland, Sweden: agreement between wholesale figures and prescription data.

Authors:  U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

5.  Measurement of drug utilization in Sweden: methodological and clinical implications.

Authors:  U Bergman; F Sjöqvist
Journal:  Acta Med Scand Suppl       Date:  1984

6.  The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden.

Authors:  U Bergman; P Elmes; M Halse; T Halvorsen; H Hood; P K Lunde; F Sjöqvist; O L Wade; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

7.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Patterns in drug utilization--national and international aspects: psychoactive drugs 1966-80.

Authors:  D J King; K Griffiths
Journal:  Acta Med Scand Suppl       Date:  1984

9.  Metabolic control in diabetic subjects in three Swedish areas with high, medium, and low sales of antidiabetic drugs.

Authors:  J Stålhammar; U Bergman; K Boman; M Dahlén
Journal:  Diabetes Care       Date:  1991-01       Impact factor: 19.112

10.  Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.